Guntram Borck

Guntram Borck

Auto-generated profile, based on publicly available information

Guntram Borck

Institute of Human Genetics, University of Ulm, Ulm, Germany

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2016 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
ICInternational Headache Genetics Consortium
International Headache Genetics Consortium
PGPadhraig Gormley
Padhraig Gormley
VAVerneri Anttila
Verneri Anttila
BWBendik S Winsvold
Bendik S Winsvold
PPPriit Palta
Priit Palta
APAarno Palotie
Aarno Palotie

5 January 2015 in Genome Research
Verified
Journal Article
Open access
PDF file
GBGuntram Borck
Guntram Borck
FHFriederike Hög
Friederike Hög
MDMaria Lisa Dentici
Maria Lisa Dentici
PTPerciliz L. Tan
Perciliz L. Tan
NSNadine Sowada
Nadine Sowada
CKChristian Kubisch
Christian Kubisch
RNA polymerase III (Pol III) synthesizes tRNAs and other small noncoding RNAs to regulate protein synthesis. Dysregulation of Pol III transcription has been linked to cancer, and germline mutations in genes encoding Pol III subunits or tRNA processing factors cause neurogenetic disorders in humans, such as hypomyelinating leukodystrophies and pontocerebellar hypoplasia. Here we describe an autosomal recessive disorder characterized by cerebellar hypoplasia and intellectual disability, as well as facial dysmorphic features, short stature, microcephaly, and dental anomalies. Whole-exome sequencing revealed biallelic missense alterations of BRF1 in three families. In support of the pathogenic potential of the discovered alleles, suppression or CRISPR-mediated deletion of brf1 in zebrafish embryos recapitulated key neurodevelopmental phenotypes; in vivo complementation showed all four candidate mutations to be pathogenic in an apparent isoform-specific context. BRF1 associates with BDP1 and TBP to form the transcription factor IIIB (TFIIIB), which recruits Pol III to target genes. We show that disease-causing mutations reduce Brf1 occupancy at tRNA target genes in Saccharomyces cerevisiae and impair cell growth. Moreover, BRF1 mutations reduce Pol III–related transcription activity in vitro. Taken together, our data show that BRF1 mutations that reduce protein activity cause neurodevelopmental anomalies, suggesting that BRF1-mediated Pol III transcription is required for normal cerebellar and cognitive development.

1 December 2012 in The American Journal of Human Genetics
Verified
Journal Article
Open access
LSLina Basel Salmon
Lina Basel Salmon
BDBruno Dallapiccola
Bruno Dallapiccola
RRRamiro Ramirez-Solis
Ramiro Ramirez-Solis
ASAlexandra Segref
Alexandra Segref
HTHolger Thiele
Holger Thiele
GBGuntram Borck
Guntram Borck
Ubiquitination plays a crucial role in neurodevelopment as exemplified by Angelman syndrome, which is caused by genetic alterations of the ubiquitin ligase-encoding UBE3A gene. Although the function of UBE3A has been widely studied, little is known about its paralog UBE3B. By using exome and capillary sequencing, we here identify biallelic UBE3B mutations in four patients from three unrelated families presenting an autosomal-recessive blepharophimosis-ptosis-intellectual-disability syndrome characterized by developmental delay, growth retardation with a small head circumference, facial dysmorphisms, and low cholesterol levels. UBE3B encodes an uncharacterized E3 ubiquitin ligase. The identified UBE3B variants include one frameshift and two splice-site mutations as well as a missense substitution affecting the highly conserved HECT domain. Disruption of mouse Ube3b leads to reduced viability and recapitulates key aspects of the human disorder, such as reduced weight and brain size and a downregulation of cholesterol synthesis. We establish that the probable Caenorhabditis elegans ortholog of UBE3B, oxi-1, functions in the ubiquitin/proteasome system in vivo and is especially required under oxidative stress conditions. Our data reveal the pleiotropic effects of UBE3B deficiency and reinforce the physiological importance of ubiquitination in neuronal development and function in mammals.

1 November 2012 in Molecular Cell
Verified
Journal Article
Closed access
GBGuntram Borck
Guntram Borck
BSByung-Sik Shin
Byung-Sik Shin
BSBarbara Stiller
Barbara Stiller
AMAviva Mimouni-Bloch
Aviva Mimouni-Bloch
HTHolger Thiele
Holger Thiele
LSLina Basel Salmon
Lina Basel Salmon

1 September 2013 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
LSLina Basel Salmon
Lina Basel Salmon
THTova Hershkovitz
Tova Hershkovitz
EHEli Heyman
Eli Heyman
MRMiquel Raspall-Chaure
Miquel Raspall-Chaure
NKNaseebullah Kakar
Naseebullah Kakar
GBGuntram Borck
Guntram Borck

11 January 2016 in Genome Research
Verified
Journal Article
Open access
PDF file
MSMalte Spielmann
Malte Spielmann
NKNaseebullah Kakar
Naseebullah Kakar
NTNaeimeh Tayebi
Naeimeh Tayebi
CLCatherine Leettola
Catherine Leettola
GNGudrun Nürnberg
Gudrun Nürnberg
GBGuntram Borck
Guntram Borck
The CRISPR/Cas technology enables targeted genome editing and the rapid generation of transgenic animal models for the study of human genetic disorders. Here we describe an autosomal recessive human disease in two unrelated families characterized by a split-foot defect, nail abnormalities of the hands, and hearing loss, due to mutations disrupting the SAM domain of the protein kinase ZAK. ZAK is a member of the MAPKKK family with no known role in limb development. We show that Zak is expressed in the developing limbs and that a CRISPR/Cas-mediated knockout of the two Zak isoforms is embryonically lethal in mice. In contrast, a deletion of the SAM domain induces a complex hindlimb defect associated with down-regulation of Trp63, a known split-hand/split-foot malformation disease gene. Our results identify ZAK as a key player in mammalian limb patterning and demonstrate the rapid utility of CRISPR/Cas genome editing to assign causality to human mutations in the mouse in <10 wk.